Abacavir
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
ABACAVIR: Drug Repurposing Evaluation Report
One-Sentence Summary
Abacavir is a nucleoside analogue reverse transcriptase inhibitor (NRTI) widely used in the treatment of HIV/AIDS. The TxGNN model has not generated any predicted new indications for this drug at this time, and there are no clinical trials or publications linked to repurposing candidates in this evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HIV infection (known from drug class; not listed in evidence pack) |
| Predicted New Indication | — (No prediction available) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not yet available |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, the TxGNN model has not produced any repurposing predictions for Abacavir. Without a predicted indication, a mechanistic plausibility assessment cannot be conducted.
From general pharmacological knowledge, Abacavir is a guanosine nucleoside analogue that inhibits HIV reverse transcriptase. It is converted intracellularly to its active metabolite carbovir triphosphate, which competes with deoxyguanosine-5'-triphosphate (dGTP) and incorporates into viral DNA, causing chain termination. This mechanism is highly specific to retroviral replication, which may limit the breadth of repurposing candidates.
Note: Detailed mechanism of action (MOA) data was not available in the evidence pack (Data Gap DG002). The description above is based on established pharmacological literature. Formal MOA data should be retrieved from DrugBank to support future analysis.
Clinical Trial Evidence
Currently no related clinical trials registered for any predicted repurposing indication.
(No predicted indications were generated by TxGNN for this candidate.)
Literature Evidence
Currently no related literature available for any predicted repurposing indication.
(No predicted indications were generated by TxGNN for this candidate.)
Taiwan Market Information
Abacavir currently holds no marketing authorizations (許可證) from the TFDA in Taiwan.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| — | — | — | No authorizations on record |
Safety Considerations
Please refer to the package insert for safety information.
Key safety data — including warnings, contraindications, and drug–drug interactions — were not available in the evidence pack (Data Gap DG001). For clinical use, the following are well-established concerns for Abacavir:
- HLA-B*5701 screening is mandatory before initiation; carriers are at high risk of a potentially fatal hypersensitivity reaction.
- Cardiovascular risk: Some epidemiological studies have associated Abacavir use with increased risk of myocardial infarction, though this remains debated.
- Lactic acidosis / hepatomegaly: A class effect of NRTIs that warrants monitoring.
Formal safety data should be sourced from the TFDA package insert (remediation per DG001).
Conclusion and Next Steps
Decision: Hold
Rationale: No repurposing indications have been predicted by TxGNN for Abacavir. Additionally, the drug is not currently marketed in Taiwan (0 authorizations), and critical safety data (package insert warnings, contraindications) remain as blocking data gaps. There is insufficient basis to advance this candidate at this time.
To proceed, the following is needed:
- TxGNN prediction results — Re-run or verify the prediction pipeline to determine if Abacavir has viable repurposing candidates
- MOA data (DG002) — Query DrugBank API for detailed mechanism of action to support future mechanistic plausibility analysis
- TFDA package insert data (DG001, Blocking) — Download and parse the package insert PDF from the TFDA website for warnings, contraindications, and prescribing information
- Market availability assessment — Confirm whether Abacavir-containing products (e.g., Ziagen®, Kivexa®, Triumeq®) are available in Taiwan under different authorization names
Report generated: 2026-04-03 | Evidence Pack version: v4 | Candidate ID: TW-DB01048-multi This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.